Phase II trial of trastuzumab (T), paclitaxel (P) and cisplatin (C) in metastatic (M) or recurrent (R) head and neck squamous cell carcinoma (HNSCC): Response by tumor EGFR and HER2/neu status

Maura L. Gillison,Bonnie S. Glisson,E. O'Leary,Barbara A. Murphy,M. A. Levine,Merrill S. Kies,Daniel W. Chan,A A Forastiere

Phase II trial of trastuzumab (T), paclitaxel (P) and cisplatin (C) in metastatic (M) or recurrent (R) head and neck squamous cell carcinoma (HNSCC): Response by tumor EGFR and HER2/neu status

2016

Maura L. Gillison
Bonnie S. Glisson
E. O'Leary
Barbara A. Murphy
M. A. Levine
Merrill S. Kies
Daniel W. Chan
A A Forastiere

5511 Background: EGFR expression is associated with poor prognosis and resistance of HNSCC to therapy. EGFR/Her2/neu heterodimers may potentiate receptor signaling and therapy resistance. T enhance...

Keywords:

Head and neck squamous-cell carcinoma
HER2/Neu Status
Paclitaxel
Receptor
Trastuzumab
Pathology
Cancer research
Medicine
Cisplatin
receptor signaling
poor prognosis
treatment resistance

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations